Director/PDMR Shareholding
Grant of Options and Notification of Transactions by Persons Discharging Managerial Responsibilities
DUBLIN, Ireland, and Boston MA, March 8, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, today announces that the Remuneration Committee has approved the grant of 3,431,350 share options ("Options") to subscribe for ordinary shares in the Company ("Shares") under the Employee Share Option Plan 2019 (the "Plan") to Joe Wiley, CEO, and Rory Nealon, CFO, details of which are set out in the table below.
The Options have an exercise price of US
| ● | |
| ● | a further |
| ● | the balance of the Options may be exercised 36 months after the date of grant. |
All Options are subject to change of control provisions and expire on the seventh anniversary of their grant.
Following the grants of these options, the following Director and Company Secretary have the following options:
| Director / Company Secretary | Options granted | Total Options now held |
| Joe Wiley | 2,031,350 | 8,468,810 |
| Rory Nealon | 1,400,000 | 6,226,823 |
PDMR Dealings
The notification of dealing forms for each Director/Company Secretary can be found below. This announcement is made in accordance with Article 19 of the EU Market Abuse Regulation 596/2014.
| 1. | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | Joe Wiley | |||
| 2. | Reason for the notification | ||||
| a) | Position / status |
Amryt Pharma Plc
NASDAQ:AMYTAMYT RankingsAMYT Latest NewsAMYT Stock Data | |||